BRCA1 gene expression in a subset of sporadic human breast Functional inactivation of BRCA1 is an important cancers. To further test this hypothesis, the cytosine methylation mechanism involved in breast cancer pathogenesis.
status of the BRCA1 promoter in 21 axillary node negative Mutation is often responsible for BRCA1 inactivation in breast cancer specimens with known levels of BRCA1 mRNA familial breast cancer, but is not responsible for the (23) were analyzed by high resolution bisulfite sequencing. decreased levels of BRCA1 seen in a subset of sporadic
The breast cancer samples analyzed in the present study are breast cancer patients. To determine if aberrant cytosine those from which tumor material was still available from the methylation of the BRCA1 promoter is associated with previous study. The results from these two analyses were decreased BRCA1 gene expression in human breast cancer, blinded from one another until the study was completed. high resolution bisulfite sequence analysis was used to
The region of the BRCA1 CpG island analyzed contains 30 analyze the cytosine methylation status of the BRCA1 CpG sites, and is located from -567 to ϩ44 relative to the promoter in 21 axillary node negative breast cancer patients BRCA1 exon1A transcription start site ( Figure 1A ). Within with known levels of BRCA1 expression. Aberrant cytosine this region is a bi-directional core promoter (-218 to ϩ1), that methylation of the BRCA1 promoter was detected in three regulates the transcription of BRCA1, as well as the NBR2 of 21 patient specimens. These three specimens also gene, which lies in a head-to-head orientation 218 bp from expressed the lowest levels of BRCA1. Results from this the BRCA1 gene (24). This short CpG-rich stretch of BRCA1 analysis show that aberrant cytosine methylation of the 5Ј flanking region contains 11 CpG sites and has previously BRCA1 promoter is directly correlated with decreased been shown to contain strong promoter activity (25), to be levels of BRCA1 expression in human breast cancer, and unmethylated in normal human mammary epithelial cells suggest that epigenetic silencing may be one mechanism (HMEC) (4) and is a target region for aberrant cytosine of transcriptional inactivation of BRCA1 in sporadic methylation in human breast cancer cell lines and tissue mammary carcinogenesis.
specimens (4, (19) (20) (21) (22) . Genomic DNA (500 ng) isolated from each of the breast cancer specimens was modified with sodium bisulfite using Mutation of the BRCA1 tumor suppressor gene is an important conditions described previously (26) . Briefly, DNA was contributing factor in hereditary breast cancer; however, denatured with 0.3 M NaOH, reacted with 3.6 M sodium BRCA1 mutations have not been detected in the sporadic form bisulfite (pH 5) at 55°C for 14 h, desalted by using a Wizard of breast cancer (1, 2) . Despite the absence of BRCA1 mutations Prep kit (Promega), desulfonated with 0.3 M NaOH, and in sporadic breast cancer, BRCA1 mRNA and protein levels finally ethanol precipitated in preparation for PCR. The BRCA1 are reduced in a subset of sporadic human breast cancers and CpG island was amplified from the bisulfite-modified DNA breast cancer cell lines (3) (4) (5) (6) (7) (8) (9) . The decrease in BRCA1 function by two rounds of PCR using nested primers specific to the is associated with the conversion to a malignant phenotype bisulfite-modified sequence of the BRCA1 CpG island. These (5,6), which can be reversed by forced re-expression of BRCA1 primer sequences and PCR conditions have been published (10). These data suggest that transcriptional and/or postpreviously (4). The resultant PCR product was cloned into the transcriptional repression of BRCA1 may participate in the TA vector pGEM-T-Easy according to the manufacturer's genesis of sporadic breast cancer.
instructions (Promega). For each breast cancer specimen, 20 One mechanism of transcriptional repression of tumor positive recombinants were isolated using a plasmid miniprep suppressor genes in human cancer is aberrant cytosine kit (Qiagen), and sequenced on an ABI automated DNA methylation of their CpG island gene promoters (11) . This sequencer. Percent methylation of each site was determined by dividing the number of methylated CpGs at a specific site
Abbreviations: HMEC, human mammary epithelial cells; PBL, peripheral blood lymphocytes.
by the total number of clones analyzed (n ϭ 20 in all cases).
From these results, the percent methylation of the 30 CpG extensive methylation of all 11 CpG sites in this region. Specimen 5 showed complete methylation at all CpG sites in sites analyzed in the BRCA1 CpG island were calculated, and are shown graphically in Figure 1B . Normal HMEC and all 20 of the bisulfite-sequenced PCR products. Specimen 4 showed allelic patterns of cytosine methylation, with~30% of normal peripheral blood lymphocytes (PBL) are unmethylated in the 218 bp stretch of the BRCA1 core promoter with only the DNA molecules showing extensive methylation throughout the promoter with the remainder being largely unmethylated low-level cytosine methylation detected at a few sporadic sites. Eighteen of the 21 breast cancer specimens were also largely ( Figure 2 ). This allelic pattern most likely reflects many contributing factors, such as the presence of contaminating unmethylated and similar to normal cells. In contrast, three of the 21 breast cancer specimens (1, 4 and 5) displayed patterns normal cells in the sample as well as heterogeneity within the tumor. As a representative example for comparison of allelic of aberrant cytosine methylation in the BRCA1 core promoter region. Two of the breast cancer specimens, 4 and 5, had patterns of cytosine methylation another specimen (specimen 11) is shown in Figure 2 . Each row of circles represents the tively, of two contiguous CpG sites (-37 and -29) within the core promoter region, whereas all other CpG sites remained cytosine methylation pattern from an individual clone, and the clones shown in Figure 2 were used to calculate the percent unmethylated. Although only two of the 30 total CpG sites analyzed in specimen 1 were methylated, we considered this methylation of each CpG site for patient specimens 4 and 11 ( Figure 1B) . In contrast to specimen 4, specimen 11 had low sufficient to be scored as aberrantly methylated because (i) these sites are unmethylated in normal tissue and (ii) this levels of cytosine methylation at a number of CpG sites throughout the entire BRCA1 CpG island; however, in specimen degree of cytosine methylation would be considered aberrant by other assays that measure cytosine methylation at one or a 11 the sites of cytosine methylation were heterogeneously distributed among the separate alleles, and no extensively few sites (e.g. Southern blot). A search of transcription factor databases with the region encompassing these two CpG sites methylated alleles were detected.
Breast cancer specimen 1 showed a unique cytosine revealed the presence of a myb consensus sequence. The myb family of DNA-binding proteins is involved in normal methylation pattern with 100 and 95% methylation, respec- beneath each graph denotes the BRCA1 core promoter region.
In this study, three of 21 (14%) breast cancer specimens showed aberrant cytosine methylation of the BRCA1 CpG island. This frequency of aberrant cytosine methylation of breast development and their binding to their DNA consensus sequence has been shown to be inhibited by cytosine the BRCA1 core promoter in the breast cancer specimens analyzed in this study is consistent with other studies that methylation (27-29); however, the functional significance of the pattern of aberrant cytosine methylation observed in have analyzed BRCA1 (3, (19) (20) (21) (22) . Using bisulfite sequencing Mancini et al. (22) detected aberrant methylation in two of specimen 1, if any, remains unknown.
The 19 CpG sites analyzed outside the BRCA1 core six breast cancer specimens. Using Southern blot analysis to analyze cytosine methylation of BRCA1, Catteau et al. detected promoter region (11 upstream and six downstream) are completely unmethylated in normal HMEC, whereas PBL showed aberrant BRCA1 methylation in 10 of 96 breast cancer specimens and Dobrovic and co-workers detected aberrant BRCA1 high methylation of the two most distal 5Ј CpG sites analyzed (-565 and -567). These sites may represent a rough 5Ј methylation in four of 18 patients over the course of two studies, whereas Magdinier et al. did not detect aberrant boundary of the CpG island, as sites immediately upstream become increasingly methylated in both normal and tumor methylation in any of the 37 patients analyzed in their study (3, (19) (20) (21) . A simple compilation of the data from our study tissue (data not shown). Similar to the results obtained for the BRCA1 core promoter region, specimens 4 and 5 were and the four studies listed above shows that 19 of 178 (11%) breast cancer specimens displayed aberrant methylation of extensively methylated at the remaining 19 CpG sites. In contrast, all other samples, including specimen 1, were largely BRCA1. Together, these data probably provide a reasonable estimate of the frequency of aberrant methylation of BRCA1 unmethylated and similar to normal cells. Although nonCpG cytosine methylation has been reported to exist in the in sporadic breast cancer. Furthermore, this estimated frequency of aberrant methylation of the BRCA1 CpG island in sporadic mammalian genome (30) , non-CpG cytosine methylation was not detected in any of the normal or tumor tissues analyzed.
breast cancer is lower than the frequency of decreased BRCA1 expression in sporadic breast cancer (7) (8) (9) , indicating that it Following completion of the cytosine methylation analysis, the level of BRCA1 gene expression for each of the breast is likely that multiple mechanisms exist for the inactivation of BRCA1 function in sporadic breast cancer. cancer specimens was unblinded. BRCA1 expression for each breast cancer specimen relative to normal HMEC (23) is
The present study extends the earlier studies on BRCA1 by providing a direct correlation between methylation of shown in Table I , as is their BRCA1 cytosine methylation status. Four of the 21 breast cancer specimens (1, 4, 5 and 11) the BRCA1 core promoter and transcriptional repression of the BRCA1 gene in sporadic human breast cancer, and suggests expressed levels of BRCA1 of one-half or less compared with 
